Patient, Physician, and Assessor Blinding in Phase III Randomized Trials in Oncology: A Meta‐Epidemiological Analysis
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Medicine"
DOI: 10.1002/cam4.71097
Abstract: Blinding mitigates bias in randomized trials and may be especially crucial for surrogate endpoints, such as progression‐free survival (PFS). Here, we characterize utilization of and factors associated with blinding in Phase III oncology trials with… read more here.
Keywords: oncology; phase iii; blinding phase; randomized trials ... See more keywords